Abstract
The prevalence of Alzheimer’s disease (AD), autism spectrum disorder (ASD), and obsessive-compulsive disorder (OCD) is higher among patients with somatic insulinopathies, like metabolic syndrome (MetS), obesity, and type 2 diabetes mellitus (T2DM). Dysregulation of insulin signalling has been implicated in these neuropsychiatric disorders, and shared genetic factors might partly underlie these observed comorbidities. We investigated genetic overlap between AD, ASD, and OCD with MetS, obesity, and T2DM by estimating pairwise genetic correlations using the summary statistics of the largest available genome-wide association studies for these diseases. Stratified covariance analyses were performed to investigate the contribution of insulin-related gene-sets. Having tested these hypotheses, novel brain “insulinopathies” were explored by estimating the genetic relationship of six additional neuropsychiatric disorders with nine insulin-related diseases/traits. Significant genetic correlations were found between OCD and MetS (rg=-0.315, p=3.9e-8), OCD and obesity (rg=-0.379, p=3.4e-5), and OCD and T2DM (rg=-0.172, p=3e-4). Stratified analyses showed negative genetic covariances between ASD and MetS/T2DM through gene-sets comprising insulin signalling and/or insulin processing genes, and between AD/OCD and MetS/T2DM through an insulin receptor recycling gene-set (p<6.17e-4). Significant genetic correlations with insulin-related phenotypes were also found for anorexia nervosa, attention-deficit/hyperactivity disorder, major depression, and schizophrenia (p<6.17e-4). Our findings suggest the existence of two clusters of neuropsychiatric disorders, in which the genetics of insulin-related diseases and traits may exert divergent pleiotropic effects. These results represent a starting point for a new research line on “insulinopathies” of the brain, which may support the development of more effective/tolerated treatment strategies for neuropsychiatric disorders.
Competing Interest Statement
AS is or has been a consultant/speaker for Abbott, Abbvie, Angelini, AstraZeneca, Clinical Data, Boehringer, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Innovapharma, Italfarmaco, Janssen, Lundbeck, Naurex, Pfizer, Polifarma, Sanofi, and Servier. BF discloses having received educational speaking fees from Medice. GP is director of Drug Target ID (DTID), Ltd. JKB has been in the past three years a consultant to/member of the advisory board of/and/or speaker for Takeda/Shire, Roche, Medice, Angelini, Janssen, and Servier. All other authors report no biomedical financial interests or potential conflicts of interest.
Funding Statement
This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 847879 (PRIME, Prevention and Remediation of Insulin Multimorbidity in Europe). NMR was supported by the European Union's Horizon 2020 Programme (H2020/2014 - 2020) under grant agreement No 667302 (CoCA) and by funding for the Dutch National Science Agenda NeurolabNL project (grant 400‐17‐602). JB was supported by a personal grant from the Netherlands Organization for Scientific Research (NWO) Innovation Program (Veni grant No 09150161910091). The analyses were carried out on the Dutch national e-infrastructure, part of the research programme Computing Time National Computing Facilities Processing Round pilots 2018 with project No 17666, which is (partly) financed by the NWO. We also thank the researchers of the consortia that provided the GWAS summary statistics used in our analyses and the participants of the cohorts to which they refer.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
We used publicly available summary statistics of genome-wide association studies conducted by external consortia, thus no specific authorisation was required from the local Ethics Committee. No individual genotypic data were used or collected.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The summary statistics of genome-wide association studies used as input for our analyses are available at the following links: for ADHD, AN, ASD, BIP, CROSS, OCD, MDD, TS - https://www.med.unc.edu/pgc/download-results/; AD - https://ctg.cncr.nl/software/summary_statistics; SCZ - http://walters.psycm.cf.ac.uk/; 2hGlu, FGlu, Fins, HbA1c, HOMA-IR - https://www.magicinvestigators.org/downloads/; BMI - https://portals.broadinstitute.org/collaboration/giant/index.php/GIANT_consortium_data_files.
